In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mind-NRG SA

Division of Minerva Neurosciences Inc.
www.mind-nrg.com

Latest From Mind-NRG SA

Bioqube Takes The Reins At J&J Innovation's JLINX

The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.

BioPharmaceutical Europe

Start-Up Execs On The Move, October 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Recent Financings Of Private Companies, October 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Device, and Pharmaceuticals sector. This month’s column covers deals announced August through September 2013.

BioPharmaceutical Medical Device

The A-List: The Trend-Shaping Series A Financings Of 2011

The capital drought that hit life science companies the past three years worked its way upstream in 2011, as several venture firms said they wouldn’t either continue in the life sciences or raise new funds. But our annual tally of life science Series A rounds presents a surprising twist: Series A rounds are up, not in blockbuster numbers by any stretch, but the downward trend of the recession years has finally been reversed. Among the year's nearly 100 Series A rounds we found plenty of oncology and peripheral vascular disease start-ups, as well as big bets on rare disease, along with some considerable nods to emerging markets.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Minerva Neurosciences Inc.
  • Senior Management
  • Contact Info
  • Mind-NRG SA
    Phone: (41) 22 737 00 00
    c/o Index Ventures, Rue de
    Jagonnant 2
    Geneva, CH-1207
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register